
|Videos|November 2, 2018
Determining Treatment Options for Select Subsets of Neuroendocrine Tumors
Author(s)Thor Halfdanarson, MD
Thor Halfdanarson, MD, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
Advertisement
Thor Halfdanarson, MD, medical oncologist at Mayo Clinic, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























